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24 weeks received a 50 mg BIW maintenance dose, and 23% of inﬂ iximab patients 
received infusions every 6 weeks. Reasons for dose increase included higher severity 
of disease, longer disease duration, loss of efﬁ cacy, overweight, joint involvement, 
higher number of previous systemic therapies received. CONCLUSIONS: Real-life 
dosing of psoriasis biologics does not always conform to the posology recommended 
in the product label, especially for high need patients. About 20% of patients being 
treated with a TNF-alpha-inhibitor seem to need a higher non-standard dose.
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OBJECTIVES: Finasteride is indicated for the treatment of male pattern hair loss at 
1 mg strength and for male symptomatic benign prostatic hyperplasia (BPH) at 5 mg 
strength. While the male pattern hair loss indication exclusivity does not expire until 
2013, the BPH indication expired in 2006. Patients have been known to purchase 
generic ﬁ nasteride in 5 mg strength and split the pills into quarters as a less expensive 
alternative to the branded 1 mg dose. The objective was to examine the uptake of 
generic ﬁ nasteride in relation to the prescribing volume of branded ﬁ nasteride for the 
treatment of male pattern hair loss to determine the impact of potential pill splitting 
on generic uptake and branded prescribing volume. METHODS: Generic and branded 
ﬁ nasteride were selected as case products. From 1992 to 2010 the volume of prescrip-
tions (TRx) were collected monthly using SDI’s VONA databases and grouped accord-
ing to branded and generic sales. RESULTS: Sales of generic ﬁ nasteride signiﬁ cantly 
accelerated immediately after launch. The compound average growth rate (CAGR) of 
TRx of branded 5 mg ﬁ nasteride between 1992 and 2006 was 23.29%. Meanwhile, 
the CAGR of generic 5 mg ﬁ nasteride from 2006 to 2010 was 96.17%, signaling an 
aggressive growth trend. Interestingly, the sales of branded 1 mg ﬁ nasteride were not 
impacted as they maintained steady growth with a CAGR of 2.49% over the four 
years since generic launch. CONCLUSIONS: One hypothesis as to the immediate 
growth of generic ﬁ nasteride after launch can be attributed to pill splitting; much of 
the volume increase was due to patients purchasing the much less expensive generic 
5 mg ﬁ nasteride and quartering the pills. However, if pill splitting did occur, it did 
not appear to impact sales of branded 1 mg ﬁ nasteride as demonstrated by a main-
tained steady growth in TRx. This suggests that patients who pill split may not have 
been prior users of branded 1 mg ﬁ nasteride.
PSS35
COST COMPARISON OF PATIENTS WITH CHRONIC HAND ECZEMA 
COVERED BY STATUTORY VS. OCCUPATIONAL HEALTH INSURANCES 
IN GERMANY
Diepgen T1, Augustin M2, Purwins S2, Posthumus J3, Kuessner D3
1University Heidelberg, Heidelberg, Germany; 2University Clinics of Hamburg, Hamburg, 
Germany; 3Basilea Pharmaceutica, Basel, Switzerland
OBJECTIVES: In Germany, patients with chronic hand eczema (CHE) can either be 
treated within the statutory health insurance system, or if CHE is suspected to be 
work-related CHE in the system of occupational health insurances. The study objective 
was to analyze the cost of CHE between both systems. METHODS: The survey was 
conducted in 24 practices in the statutory health insurance system and 2 specialized 
centers of the occupational health insurances. Patients with CHE refractory to potent 
topical treatments were included. Patient characteristics/status and resource use were 
elicited from patients and physicians. Costs were evaluated from the societal perspec-
tive (using insurance speciﬁ c tariffs). Regression models were employed to compare 
the direct and indirect costs across both data sets. RESULTS: A total of 223 patients 
in the statutory health system and 87 patients in the occupational health insurance 
system were included in this study. The patients’ severity was similar across both 
samples. The yearly direct and indirect costs per patient are c1742 and c386 in the 
statutory health insurance system as well as c3309 (c2534 according to statutory 
health insurance tariff) and c3422 in the occupational health system. The indirect 
costs are more pronounced among patients with work-related CHE. a comparison of 
direct and indirect costs reveal higher costs for patients covered by occupational health 
insurances (P < 0.01); however, no cost differences between both systems can be 
detected after controlling for treatment stage and tariff differences. CONCLUSIONS: 
Differences in the costs between both systems can be explained by different treatment 
mixes, as direct costs are similar across treatment stages. As a result of longer absences 
from work, the indirect costs of patients with work-related CHE are higher. This may 
lead to the use of more effective and costly treatment strategies in this patient group.
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OBJECTIVES: Cataract surgery is one of the most efﬁ cacious medical strategies and 
one of the most frequently performed operations in developed countries. Organization 
for Economic Co-operation and Development (OECD) collects information on this 
topic but their data are not updated often. The aim of this survey was to estimate the 
number and costs of cataract surgeries performed in 14 European countries and the 
potential costs associated with astigmatism. METHODS: Cataract surgery numbers 
were estimated from available databases. Costs associated with cataract surgery were 
based on ofﬁ cial tariffs of local health care systems. The number of surgeries and the 
costs per 100 000 people were estimated for each country to allow comparisons. 
Astigmatism related costs were also explored. This survey was carried out in 14 
European countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, 
Ireland, Italy, the The Netherlands, Portugal, Spain, Sweden, and the UK. RESULTS: 
Information was fully available in 10 countries and partly available in OECD statistics. 
Cataract surgery rates were in the range of 444 to 1,006 operations per 100,000 
people in the countries with complete information. All the countries were using a DRG 
system for costs and tariffs. Costs of operations were highly variable, depending on 
complications, type of surgery, and surgical setting (outpatient or inpatient). Average 
cost of surgery ranged across the countries from c875 to c2000. Average cost per 
inhabitant was estimated at between c5 and c15 per year. Astigmatism associated 
costs are never taken into account. CONCLUSIONS: Cataract surgery is performed 
in a large part of the European population with variations across countries. Further 
research needs to be conducted to explain differences between countries.
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OBJECTIVES: Cataract surgery is one of the most efﬁ cacious medical strategies and 
one of the most frequently performed operations in developed countries. The aim of 
this survey was to establish an assessment of the available guidelines for cataract 
surgery in Europe. METHODS: The search was performed with a two steps design. 
a classical literature search was performed using the method elaborated by the French 
Haute Autorité de Santé directly through the Internet. a second step was to interview 
local experts to identify grey literature in local languages that could be available 
through local health authorities or medical societies. This survey was carried out in 
15 European countries: Austria, Belgium, Denmark, Finland, France, Germany, 
Greece, Ireland, Italy, the The Netherlands, Portugal, Spain, Sweden, Switzerland, and 
the UK. RESULTS: The classical literature search identiﬁ ed 15 documents that could 
be considered as guidelines on cataract surgery. They were mainly written in English; 
only one originated in Europe. General guidelines (n = 9) considered the initial check-
up and indications for cataract surgery, surgical techniques and follow-up. Speciﬁ c 
guidelines were found covering the type of implants (n = 1), surgical technique (n = 
1) and the anaesthesia technique (n = 4). This latter group was mainly extracted from 
the Cochrane database. The second step of the research identiﬁ ed 10 local guidelines 
in 7 European countries. These guidelines were rarely complete (n = 2) and envisaged 
some speciﬁ c aspects of the operation (n = 8) or the implants (n = 2). CONCLUSIONS: 
Guidelines on cataract surgery are available at an international level but are rarely 
provided at a country level in Europe. 
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OBJECTIVES: QoL data collected in clinical trials traditionally involves self-report 
or face to face interviewer-administered questionnaires. The former may result in 
missing data/errors; the latter requires trained interviewers, possibly adding variability 
to the data collected (when multiple sites are involved) or bias in terms of social 
desirability. To improve the quality of data collected in a clinical trial for DME, we 
employed a centralised call centre methodology. METHODS: QoL data were collected 
in a large multicenter trial, NCT00605280, evaluating the safety and efﬁ cacy of 
pegaptanib sodium in patients with DME. An interface between the trial database and 
the independent call centre was established. Once subjects entered the trial, subject 
identiﬁ er, status and visit history were automatically generated and the call centre 
agent received subject contact and visit details directly from the trial database. The 
agent contacted the subjects to schedule interviews at the appropriate time points. Five 
call backs were allowed per call to ensure questionnaire completion. All QoL responses 
were recorded directly into the call centre database. The status of the QoL visit 
information and completions were sent to the trial database weekly. RESULTS: The 
two QoL measures (National Eye Institute Visual Function Questionnaire 25 and 
EuroQol Group’s EQ-5D questionnaire) had high completion rates; 99.8% of com-
pleted interviews included both questionnaires (57% successfully completed on initial 
attempt, 23% on the second attempt of contacting the subject). Only 4% of data were 
missing; 26 minutes was the average completion time. CONCLUSIONS: This call 
centre methodology resulted in high questionnaire completion and little missing data. 
This approach demonstrates robustness and offers a feasible alternative for question-
naire administration, particularly in visually impaired people. Administration in the 
subject’s home maybe advantageous and centralised interviewers (instead of site inter-
viewers) potentially reduced the variability in questionnaire response. Further research 
comparing methods is indicated. 
